Event Date: May 22, 2018
FDA designation of a companion diagnostic test has key implications for pharmacy payers. Coordinating medical benefit and pharmacy policies regarding companion diagnostics and pharmaceuticals may be a worthwhile consideration for your plan.
The presentations within this webinar will discuss the OlympiAD data and the resulting FDA companion diagnostic indication for BRACAnalysis CDx in considering treatment options for patients with metastatic breast cancer. Results and analysis from a survey distributed to AMCP members will be discussed within the webinar.
Click here for additional information and registration details.
